EWTX Stock Analysis: Buy, Sell, or Hold?
EWTX - Edgewise Therapeutics, Inc. Common Stock
$28.15
-0.63 (-2.19%)
▼
5d:
-1.61%
30d:
+14.71%
90d:
+72.38%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 02, 2026
27d
Get Alerted When EWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EWTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: EWTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: EWTX is currently trading at $28.15, which is considered slightly high relative to its 30-day fair value range of $24.35 to $28.63.
Technical Outlook: Technically, EWTX is in a strong uptrend. Immediate support is located at $25.92, while resistance sits at $30.25.
Market Sentiment: EWTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.17 (+35.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EWTX is in a strong uptrend. Immediate support is located at $25.92, while resistance sits at $30.25.
Market Sentiment: EWTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.17 (+35.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$24.35 -
$28.63
Company Quality Score
60/100
(HOLD)
Options IV Signal
17th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 17th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.6% below Wall St target ($38.17)
Fair Price Analysis
30-Day Fair Range
$24.35 -
$28.63
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.96
(14.1%)
Support & Resistance Levels
Support Level
$25.92
Resistance Level
$30.25
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-14.22
Wall Street Target
$38.17
(+35.6%)
Last updated: February 02, 2026 4:31 AM ET
Data refreshes hourly during market hours. Next update: 5:31 AM
Data refreshes hourly during market hours. Next update: 5:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan J Russell
SELL
100000 shares
2025-08-26
Alan J Russell
SELL
1907 shares
2025-08-12
Joanne M Donovan
SELL
2862 shares
2025-08-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 59 HOLD |
